According to The Insight Partners – The global Gallium-68 market is gaining considerable momentum as the healthcare industry increasingly embraces the power of nuclear medicine in the early and accurate detection of cancer and other serious conditions. Gallium-68 (Ga-68) is a positron-emitting radioisotope at the forefront of a new generation of diagnostic imaging, offering clinicians unprecedented precision in identifying and staging diseases that were previously difficult to detect. The market is projected to grow from US$ 782.36 million in 2022 to US$ 1,070.34 million by 2030, registering a CAGR of 4.0% during the forecast period from 2022 to 2030.
Understanding Gallium-68 and Its Diagnostic Role
Gallium-68 is produced from a germanium-68/gallium-68 (68Ge/68Ga) generator and has a half-life of 68 minutes, making it well suited for use as a radiotracer in Positron Emission Tomography (PET) imaging. Its short half-life enables high-quality imaging with minimal radiation exposure to patients, while its ability to be attached to specific targeting molecules allows for precise localization of disease sites within the body. Among its most significant clinical applications is the Ga-68 PSMA-11 PET scan, which is widely used to detect prostate cancer cells with remarkable sensitivity and specificity. It is also extensively used to identify somatostatin receptor-positive neuroendocrine tumors in both adults and children, representing a transformative advancement over conventional imaging modalities.
Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00029992
Key Market Drivers
The most fundamental driver of the Gallium-68 market is the rising global prevalence of prostate cancer and neuroendocrine tumors. Prostate cancer is one of the most common cancers worldwide, with the International Agency for Research on Cancer estimating that the number of cases will rise from approximately 1.47 million in 2022 to nearly 1.83 million by 2030 and as many as 2.88 million by 2050. The demand for accurate diagnostic tools to detect, stage, and monitor prostate cancer is therefore growing substantially, directly fueling adoption of Ga-68-based PET imaging.
Neuroendocrine tumors also represent a significant disease burden. According to the American Society of Clinical Oncology, nearly 12,000 people in the United States are diagnosed with a neuroendocrine tumor every year. Gallium-68 provides a critical diagnostic advantage in this context, enabling accurate tumor localization that guides effective treatment planning and improves patient outcomes.
The broader surge in the use of nuclear imaging techniques is a powerful complementary driver. Advancements in hybrid imaging technologies, the development of novel radiopharmaceuticals, and the increasing application of molecular imaging based on the tracer principle are collectively elevating the role of nuclear medicine in modern oncology, neurology, and cardiology.
Market Segmentation
By application, oncology dominates the market and is expected to register the highest CAGR throughout the forecast period, with prostate cancer and neuroendocrine tumors as the primary subcategories. Neurology and cardiology represent growing secondary applications as research expands the clinical utility of Ga-68 imaging beyond oncology. By end user, hospitals hold the largest market share and are projected to maintain the strongest growth trajectory, while diagnostic and imaging centers represent an important and expanding channel.
Get Full Copy of This Report @ https://www.theinsightpartners.com/buy/TIPRE00029992
Regional Landscape
North America dominates the global Gallium-68 market, driven by advanced healthcare infrastructure, high cancer incidence rates, and significant investment in radiopharmaceutical innovation. The rising cancer patient count in the United States, projected to grow from 2.28 million cases in 2020 to 3.12 million by 2040, is a particularly compelling growth catalyst. Europe follows with a strong research foundation and well-established nuclear medicine infrastructure. Asia-Pacific is emerging as a rapidly growing region, supported by increasing cancer awareness, improving healthcare access, and growing investment in nuclear medicine capabilities across China, India, and Japan.
Recent Developments and Competitive Landscape
The competitive landscape reflects active innovation and regulatory progress. In December 2023, Ariceum Therapeutics was granted US and Canadian patents for a Gallium-68 radiopharmaceutical production kit that enables the production of multiple patient doses in a single vial in one simple step, dramatically improving production efficiency. In March 2023, Telix Pharmaceuticals received FDA approval for its Illuccix Ga-68 gozetotide injection preparation kit for screening patients with metastatic prostate cancer recommended for Lutetium-177 PSMA-directed therapy, marking a significant milestone in theranostic medicine.
Key players operating in this market include Novartis AG, Telix Pharmaceuticals, IRE-ELiT SA, ITM Medical Isotopes GmbH, Eckert and Ziegler Radiopharma GmbH, ARTMS Inc, IBA Radiopharma Solutions, Cardinal Health, Rosatom, and Evergreen Theragnostics Inc. These companies are focused on developing new production technologies, expanding generator portfolios, and securing regulatory approvals across global markets.
The Gallium-68 market stands as a cornerstone of precision oncology, offering a powerful diagnostic window into some of the world’s most prevalent and challenging cancers, and positioned for sustained growth as nuclear medicine continues to redefine the boundaries of modern healthcare.
Top Trending Reports @
Biotechnology Market Share, Demand & Growth by 2034
Genomics Market Dynamics and Developments by 2031
Molecular Biology Enzymes, Kits, and Reagents Market Size and Competitive Analysis by 2028
About Us –
The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.
Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish